Publikationen in Zusammenarbeit mit Forschern von Copenhagen University Hospital (11)

2024

  1. ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

    Blood, Vol. 144, Núm. 11, pp. 1193-1205

  2. Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy—An observational Ponte di Legno Toxicity Working Group Study

    British Journal of Haematology, Vol. 205, Núm. 4, pp. 1450-1459

  3. The ECHO recommendations for dealing with vinblastine shortage affecting standard treatment of systemic Langerhans cell histiocytosis

    Pediatric Blood and Cancer

2022

  1. Characteristics of white blood cell count in acute lymphoblastic leukemia: A COST LEGEND phenotype–genotype study

    Pediatric Blood and Cancer, Vol. 69, Núm. 6

  2. Hypersensitivity to Pegylated E.colia sparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group

    European Journal of Cancer, Vol. 162, pp. 65-75

2021

  1. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

    The Lancet Haematology, Vol. 8, Núm. 7, pp. e513-e523

  2. Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies

    Cancers, Vol. 13, Núm. 11

2018

  1. Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis

    Blood, Vol. 132, Núm. 19, pp. 2088-2096

2017

  1. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

    Journal of Pediatrics, Vol. 189, pp. 72-78.e3

  2. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700

2014

  1. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

    Arthritis and Rheumatology, Vol. 66, Núm. 10, pp. 2871-2880